OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
© 2020 MJH Life Sciences™ and BioPharm International. All rights reserved.
Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.
A balance must be achieved between debris and impurity removal and maximizing product quality and yield.
Facility and equipment design are important, but the team and its experience matter most.
New therapeutics modalities and the need for greater process efficiency are driving technology development.
Many antibody-drug conjugate therapies are in the pipeline; only a handful have been approved. What are the bottlenecks?